CVS 2018

2018 CVS Final Program

2018 CVS Exhibit and Poster Hall Activity Guide

Past Meeting Materials


2018 ASM CVS Supporters

The American Society for Microbiology would like to recognize the following companies for their support of the ASM CVS: 

Hologic Main Logo Small 2 17

Roche


Follow @ASMicrobiology on Twitter and use #ASMCVS for the latest meeting updates! 

 

Industry & Science Workshops

Watch for FREE! View Industry Workshops from this year’s ASM Clinical Virology Symposium
Catch-up on these cutting-edge industry presentations discussing the field’s latest developments.

Please Note: To view the workshops in full screen, please click the icon in the lower right hand corner of player.
 



Managing CMV Infection and Realizing Operational Efficiencies in Your Laboratory

Supported by Abbott Molecular
(PACE Accredited. This video requires registration through LabRoots' website.)
CVS18 Abbott CaptureImage
  

Speakers:
Clinical Impact of Missing CMV Viremia inHe matopoietic Stem Cell Transplant Patients
Dr. John McKinnon, M.D., Henry Ford Hospital

Streamlining and Standardizin g MolecularTesting Through Consolidation
Dr. Frederick (Rick) Nolte, Ph.D., Medical University of South Carolina

Overview:
Human cytomegalovirus (CMV) infection is prevalent in transplant patients, and is frequently associated withsignificant morbidity and mortality. In CMV positive recipients of allogeneic human stem cell transplantation, the incidence of viral reactivation can be seen in up to 80% of patients, with up to 30% of these patients ultimately developing clinically significant CMV disease. The potential clinical impact of missing CMV viremia cannot be understated.

In the first part of this presentation, Dr. John McKinnon will present data from his study comparing two commercial assays for the quantitation of CMV and potential relationship with mutations on UL54.

In the second part of this presentation, Dr. Rick Nolte present shis experience with consolidating IVDs ad LDTs on the versatile m2000 molecular platform. Consolidation of laboratory testing on a single automated molecular platform can result in many benefits to the laboratory, namely by reducing the number of redundant instruments, streamlining operations, and standardizing testing - all of which can translate into considerable cost savings and improved quality of care.


The Future of Pneumonia Diagnostics: How Multiplex PCR Testing will Impact Patient Care

Supported by BioFire Diagnostics

Speakers:
How Multiplex PCR will Change Laboratory Medicine
Blake Buchan, Ph.D., Assistant Professor of Pathology, Medical College of Wisconsin

Christine Ginocchio, Ph.D., MT (ASCP), BioFire Diagnostics Vice President, Scientific and Medical Affairs bioMerieux Vice President, Global Medical Affairs

Overview:
The complex microbiology of lower respiratory samples has thwarted attempts to develop broad molecular diagnostic panels in this area. BioFire has developed a test, currently investigational use only, which will identify 18 bacteria, 9 viruses, and 7 genetic markers of resistance in commonly collected lower respiratory specimens all in one hour. Come learn more about how this panel could impact your laboratory.


The Reimbursement Landscape for Multiplex PCR Testing

Supported by BioFire Diagnostics

Speakers:
Addressing Challenges in Reimbursement for Multiplex PCR Testing
Lynn Todd, MLS (ASCP) Lab Director, Campbell County Health, Black Hills State University, Casper, WY

Melissa B. Miller, Ph.D., D(ABMM), Professor, Pathology & Laboratory Medicine, Director, Clinical Molecular Microbiology Laboratory, Associate Director, Clinical Microbiology-Immunology Laboratory, UNC School of Medicine, Chapel Hill, NC

Overview:
Reimbursement for laboratory procedures is a growing concern. Come hear from both experts on how they are confronting this issue.


System Standardization of Respiratory Testing: It Works!

Supported by Cepheid

Speakers
Standardize Your Diagnostics for Economic & Patient Benefits
Rochelle Odenbrett, Senior Executive Director of Laboratories, Sanford Health

Why Test RSV in Adults?
Sharon Nachman, M.D., Chief of Division of Pediatric Infectious Diseases, Director of the Office of Clinical Trials, Professor of Pediatrics, SUNY Stony Brook

Overview:
Standardization of quality care throughout your hospital provides multiple opportunities for improvement. Learn why and how Sanford Health implemented system-wide molecular diagnostic standardization of respiratory testing in 70 of their hospital and clinic locations. Explore the benefits and pitfalls of standardization initiatives. Plus, hear the physician perspective on the importance of testing for HSV in adults.

The Latest In Neonatal HSV Molecular Testing and Navigating the New C. difficile Guidelines

Supported by DiaSorin Molecular

Speaker:
Addressing unique sample and data needs associated with neonatal and infant HSV diagnosis
Amanda T. Harrington, Ph.D,. D(ABMM), Director, Clinical Microbiology Laboratory Associate Professor, Pathology and Laboratory Medicine Loyola University Medical Center

Overview:
A laboratory perspective reporting the variety of samples received for neonatal and infant HSV diagnosis, the data currently available and clinical implications. Data stratified by age and sample types for both neonatal and infant HSV diagnostic needs will be presented.

Speaker:
New guidelines on diagnosis C.difficile infection — one size fits all?

Siu-Kei (Jacky) Chow, Ph.D., D(ABMM), Technical Director Infectious Diseases Diagnostics MultiCare Health System

Overview:
Clostridium difficile and C. difficile infection remain as topics of debate that carry implications for infection control, hospital reimbursement, public reporting, and most importantly, patient care. With the recent updated guidelines by IDSA/SHEA, laboratories find themselves revisiting the advantage and disadvantages of current approaches. This presentation will discuss one laboratory’s experience on diagnosing C. difficile infection, the new guidelines, best practice strategies, as well as laboratory testing challenges.


Clinical Utility and Workflow of Aptima® HIV and Hepatitis Assays on the Panther® System

Supported by Hologic, Inc

Speakers:
Evaluation of the Aptima® HCV Quant Dx and HBV Quant Assays on Serum
Benjamin Pinsky, M.D., Ph.D., Associate Professor of Pathology and of Medicine (Infectious Diseases), Stanford University Medical Center

Aptima® HIV-1/HCV/HBV Assays and Workflow Performance in Comparison to Other Next-Generation Diagnostic Solutions
Dr. Rafael Delgado, Servicio de Microbiología, Hospital Universitario 12  de Octubre

Overview:
Aptima® viral load assays on the Panther® system utilize transcription mediated amplification (TMA) and real-time fluorescence detection for quantification of HIV, HCV and HBV. Published data indicate that these assays are highly accurate and precise with wide dynamic ranges that can confidently be used detect and quantify RNA/DNA in clinical trials and in clinical practice. Further, technologies such as TMA facilitate efficient processing and workflow management necessary to meet healthcare mandates for expanding services and reducing cost while maintaining the highest levels of quality. The first presentation at this symposium will demonstrate the clinical utility of the hepatitis assays for longitudinal HCV/HBV viral load monitoring. The second presentation in this symposium reveals workflow advantages of Aptima assays on the Panther system compared to other next-generation diagnostic solution (Roche cobas 6800 and Beckman DxN VERIS).

Evolve Your Syndromic Respiratory Testing with the Panther Fusion® System

Supported by Hologic, Inc

Speakers:
Panther Fusion Respiratory Assays: A Flexible Approach to Syndromic Respiratory Testing
Jim Dunn, Ph.D, D(ABMM), Director, Medical Microbiology and Virology Texas Children’s Hospital, Associate Professor, Pathology & Immunology Baylor College of Medicine

Performance Evaluation of the Panther Fusion Flu A/B/RSV Assay for Influenza Detection
Kathleen Stellrecht, Ph.D., D(ABMM), HCLD(ABB), Director of Microbiology, Professor of Pathology and Laboratory Medicine, Professor of the Center for Immunology and Microbial Diseases Albany Medical Center

Overview:
Respiratory viruses are responsible for a wide range of acute respiratory tract infections including the common cold, influenza and croup, and represent the most common cause of acute illness in the United States. Accurate and timely diagnosis of the cause of respiratory tract infections has many benefits. They
include improved treatment of the patient by ensuring appropriate antiviral therapy; decreasing the overall cost of care; reducing the potential for further development of antimicrobial resistance due to excessive and inappropriate use of antibiotics; assisting infection control personnel in providing appropriate measures to minimize nosocomial spread; and providing valued information to public health authorities regarding which viruses are circulating in the community. In this session, Dr. Jim Dunn will share comparative data between the Panther Fusion® Respiratory assays and 3 other IVDs for respiratory testing. He will also discuss the impact of a flexible, modular solution for syndromic respiratory testing on a pediatric patient population. Dr. Kathleen Stellrecht will discuss the importance of a robust influenza design in NAAT testing and share comparative performance data for the Panther Fusion® Flu A/B/RSV assay. Discover how the fully automated, random access Panther Fusion system provides a novel, modular approach to syndromic testing for respiratory viruses.

 



The following workshops were not recorded at this year's meeting, but details are provided below as a summary of the other workshops that took place in West Palm Beach.

BioCode Gastrointestinal Pathogen Panel: An Efficient, Automated Solution for High-Volume GI Pathogen Testing

Supported by Applied BioCode

Speakers:
BioCode Gastrointestinal Pathogen Panel: An Efficient, Automated Solution for High-Volume GI Pathogen Testing.
Dr. Michael Aye, Vice President, Product Development, Applied BioCode
Dr. Anami Patel, Vice President, Genomic Operations & Development, Poplar Healthcare in Memphis, Tennessee

Overview:
Learn about the automated BioCode MDx 3000 System with 18-Plex Gastrointestinal Pathogen Panel* and how it can improve the workflow for high throughput syndromic testing. The system offers both throughput and cost-savings advantages over cartridge-based systems. This flexible and highly cost effective platform can produce results from 188 clinical samples in <8 hours with minimal hands-on time. The new 18-plex BioCode Gastrointestinal Pathogen Panel, which was submitted to the FDA in January, includes targets for the 18 most common pathogenic bacteria, viruses and parasites.

Performance and Genotyping Results from the BD Onclarity™ HPV Assay US Clinical Trial

Supported by BD

Speaker:
Charles Cooper, M.D., Vice President, Medical Affairs, Life Sciences

Overview:
The BD Workshop will cover the following topics: The BD Onclarity™ clinical trial review, performance by intended use — ACUS triage, Co-testing and primary screening and results in vaccinated vs. unvaccinated cohorts.


OPTIMIZED LYOPHILIZATION: Provide Your Customers with Molecular Diagnostic Assays with Years of Room Temperature Stability and Simplified User Experience

Supported by BIOLYPH LLC

Speaker:
OPTIMIZED LYOPHILIZATION
Timothy E. Pearcy

Overview:
BIOLYPH provides lyophilization services for PCR Master Mixes and other molecular diagnostic reagents for molecular diagnostic assay developers and manufacturers. A single Master Mix LyoSphere™ can contain Enzymes, Oligonucleotides, Dyes, RNAse Inhibitors, Cations, dNTPs, Buffers and Excipients in a stable, consistent form, which rehydrates instantly and can be packaged into virtually any device format. Timothy Pearcy, Founder and Managing Director of BIOLYPH, details BIOLYPH’s capabilities to provide lyophilized Master Mixes for molecular diagnostic assays that deliver simplified product storage and transport, higher product stability over broader temperature tolerances, longer product shelf-life, and superior end-user ease of use.


Evaluation of the Curetis Unyvero Multiplex PCR Lower Respiratory Infection Panel

Supported by Curetis USA

Speakers:
Evaluation of the Curetis Unyvero Multiplex PCR Lower Respiratory Infection Pane
Dr. Melissa Miller, Ph.D., D(ABMM), F(AAM), Director, Clinical Molecular Microbiology Laboratory at the University of North Carolina School of Medicine

Unyvero Technology Overview
Faranak Atrzadeh, Director of Scientific Affairs, Curetis USA

Overview:
Dr. Melissa Miller, Ph.D., D(ABMM), F(AAM), professor of pathology and laboratory medicine and Director, Clinical Molecular Microbiology Laboratory at the University of North Carolina School of Medicine will present UNC Health Care’s findings in their evaluation of the Curetis Unyvero Multiplex PCR Lower Respiratory Infection panel. Please join Curetis and Dr. Miller in this enlightening workshop session.

How to get qPCR for less without sacrificing quality

Supported by Diagnostics.ai

Speakers:
pcr.ai: from the sample to the answer for less
Aron Cohen, CEO, pcr.ai

pcr.ai: how to use the system in less than five minutes in your own lab
Aron Cohen, CEO, pcr.ai

Overview:
To run qPCR LDT tests or kits requires expertise both in qPCR and how to troubleshoot issues. This can make qPCR resource-intensive both in terms of money and of time. In this workshop, we will discuss how and why pcr.ai can improve your test-workflow whilst saving money.

We will discuss issues that even experienced labs struggle to solve, lessons we learnt from high and low-throughput labs, strategies for setting up and optimizing qPCR testing and how to ease HIPAA compliance for qPCR.


ELITe InGenius®: Advancing the Future of Molecular Testing

Supported by ELITechGroup Molecular Diagnostics

Speakers:
Benefits of ELITe InGenius® Use in a Children’s Hospital: Performance and Workflow Impact
Sue Kehl, Ph.D., Director, Microbiology, Immunology and Molecular Infectious Disease Laboratory, Children’s Hospital of Wisconsin

Validation and Routine Use of the ELITe InGenius® System for HSV 1/2 and CMV Testing: Presentation
of Analytical and Clinical Data
Suzane Silbert, Clinical Scientist, Esoteric/R&D Laboratory, Tampa General Hospital

Overview:
The ELITe InGenius system is an open, integrated and easy to-use sample-to-result solution. ELITe InGenius automatically performs nucleic acid extraction, quantitative PCR, and results interpretation on one single platform with unprecedented flexibility and efficiency, enabling laboratories to run parameters according to their specific needs. ELITe InGenius enables laboratories to streamline workflow, reduce hands-on time and limit the risk of errors while ensuring high-performance results.

The ELITechGroup workshop will include lectures from distinguished speakers describing their laboratory experience using the ELITe InGenius® system and its breakthrough performance. Of special note, a presentation will be included giving an exclusive look at the early clinical performance of the upcoming HSV 1/2 assay, the results correspond with the 510(k) application for ELITe InGenius and HSV1/2 assay submitted
last Winter. The FDA clearance is anticipated in 2018.


Improving Patient Care with ePlex®: The True Sample-to Answer Solution™

Supported by GenMark Dx

Speakers:
The Clinical Impact of Rapid Winter Respiratory Virus Testing in the UK
Dr. Barry Neish, B.Sc., M.Sc., M.Res., Ph.D., F.R.C.Path., Consultant Microbiologist, York Teaching Hospitals NHS Foundation Trust

Moderator:
Natalie N. Whitfield, Ph.D., D(ABMM), Director of Scientific and Medical Affairs, GenMark Diagnostics

Overview:
GenMark Diagnostics is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. In this workshop, you will learn about the clinical impact of implementing of the ePlex Respiratory Panel during the 2017-2018 flu seasons.

Challenges and solutions to the dynamic respiratory market: An open discussion with laboratory experts on the requirements for testing solutions in different healthcare systems.

Supported by Luminex

Speakers:
Margie Morgan, Ph.D., Professor, Pathology Scientific Director, Microbiology at Cedar Sinai Health
Gregory J. Berry, Ph.D., D (ABMM), Director, Molecular Diagnostics & Assistant Director, Infectious Disease at Diagnostics at Northwell Health
Bijaya Dhakal, Ph.D., D (ABMM), Director, Molecular Laboratory at Sonic Reference Laboratory at Sonic Reference Laboratory
Brian A. Koeneman, Ph.D., Laboratory Sciences of Arizona, Sonora Quest Laboratories, Tempe

Overview:
The current market for respiratory testing is dynamic and complicated with technologies of varying complexity, pathogen coverage, and turnaround times. The task of selecting a platform or platforms is further complicated by the need to service multiple patient populations while navigating through increased reimbursement scrutiny. A panel of laboratorians serving a variety of healthcare systems will discuss how they have addressed some of these challenges and the direction in which they see this market going.


Method Comparison for Equivalence of CMV Viral Loads between the new automated QIAsymphony and the semi-automated EZ1 workflow

Supported by QIAGEN, Inc

Speaker:
Method Comparison for Equivalence of CMV Viral Loads between the new automated QIAsymphony and the semi-automated EZ1 workflow
Belinda Lieberman

Overview:
Cytomegalovirus (CMV) infection is potentially life-threatening for the immunocompromised such as transplant recipients. Rapid detection and quantitation of this virus aids in prompt and effective treatment for these patient groups. CMV extraction, detection, and quantitation of plasma samples collected in EDTA, using the new QIAsymphony RGQ MDx and the EZ1 Advanced XL workflows, were evaluated and compared to determine workflow equivalence.

Beyond the Patient’s Flu Test Result: Influenza Surveillance, Resource Planning and Laboratory Management

Supported by Quidel Corporation

Speakers:
Beyond FluTest Results: Influenza Surveillance, Resource Planning & Laboratory Management
John Tamerius, Ph.D., Sr. Vice President, Strategic & External Affairs

Lesions! Herpes or Shingles and how fast do you want to know?
Scott McClellan, B.S., MT (ASCP); Chief Technologist, Molecular Infectious Disease R&D, Michigan Medicine

Overview:
Learn how providing information beyond a traditional flu diagnosis can improve patient management. You’ll also learn about the importance of testing for VZV using HSV 1+2 with results in an actionable timeframe, helping improve laboratory efficiencies.


Workshop Talks for ASM Clinical Virology Symposium

Supported by RTTMDx

Speaker:
Validation Methodology for NGS-based HIV-1 Drug Resistance Assay: Performance, Data Analysis, and Quality Assurance
Dun Liang, Ph.D., Executive Director ViroDx, LLC.

Overview:
The utility of NGS HIV-1 drug resistance assay in the clinical laboratory is limited by barriers such as: well controlled analytical validation strategy, readily available established quality system; sample-in-report-out data pipeline; cost per sample coupled with batching. We will talk about solutions to these barriers.

Speaker:
Core Concepts of a Complete Genotyping Solution
Robert M. Lloyd, Jr., Chief Scientific Officer, RTTMDx, Chairman of the Board RTTMDx

Overview:
CoreFAST a novel low complexity technology for high throughout cost effective Mutation Screening Test (MST) utilizing RTTMDx exclusive CoreFLEX™ testing model that includes comprehensive and integrated reflex testing kits and a single instrument, TSASS Sequencer, for confirmatory sequencing with the GeneTHINK® CoreSEQ® HIV-1 PR/RT DR-Select kit (former TRUGENE®).


Partnership Supports Your Molecular Infectious Disease Test Development

Supported by Thermo Fisher Scientific

Speakers:
DNA-free enzymes for infectious disease test development
Todd Howren, Associate Director, Molecular Biology, OEM Sales, Thermo Fisher Scientific

Assay development for the ELITe InGenius® sample to results platform and conventional ASR’s: A B2B success story spanning 20 Years
Carl Hilliker, Ph.D., Sr. V.P., Business Development, ELITechGroup

Development of a novel, rapid molecular Test for complicated urinary-tract infections (cUTI) and prediction of antimicrobial resistance.
OpGen

Overview:
Thermo Fisher Scientific’s OEM team enables molecular diagnostics developers to bring robust assays to market quickly. Learn how molecular diagnostic companies have developed viral assays in partnership with Thermo Fisher Scientific, and about how DNA-free enzymes are enabling enhanced sensitivity in infectious disease applications.

 

TPL_asm2013_ADDITIONAL_INFORMATION

TPL_asm2013_SEARCH

95011